干旱区生态环境知识资源中心(Arid): QUANTITATIVE ANALYSIS OF SORAFENIB AND NILOTINIB IN HUMAN PLASMA BY SPE-LC-MS

Arid

DOI	10.31925/farmacia.2023.5.17
	QUANTITATIVE ANALYSIS OF SORAFENIB AND NILOTINIB IN HUMAN PLASMA BY SPE-LC-MS
	Popescu, Monica Denisa Elena; Manda, Costel-Valentin; Calucica, Daniela Maria; Gaman, Amelia Maria; Neamtu, Johny; Bita, Andrei; Mateescu, Olivia Garofia; Neamtu, Simona-Daniela; Raileanu, Stefan; Stanca, Liliana; Croitoru, Octavian
通讯作者	Manda, CV
来源期刊	FARMACIA
ISSN	0014-8237
EISSN	2065-0019
出版年	2023
卷号	71 期号:5 页码:1024-1031
英文摘要	Sorafenib and nilotinib are two tyrosine kinase inhibitors (TKIs) used in the treatment of cancer. Plasmatic levels of the drugs show an important variability, so determining plasma concentration of the drugs, benefits in cancer treatment can be improved. Most papers published so far in the literature use protein precipitation followed by liquid chromatography tandem mass-spectrometry (LC-MS/MS) as separation and detection method. With this work, we propose an alternative method for the analysis of both TKIs in human plasma. Solid phase extraction (SPE) involving Oasis PRiME HLB (R) cartridges was our choice for plasma clean-up procedure. Extraction recoveries were at least 85%. Chromatography was performed by an ultra-high-performance liquid chromatographic system (UHPLC), using a C18 (4.6 x 50 mm) column and a mobile phase consisting of ammonium acetate/acetic acid-acetonitrile gradient elution. Detector was a simple mass spectrometer (MS) in Single Ion Recording (SIR) mode. Intra-and inter-day precision data for both TKIs were 3.8 7.6% and 4.5 8.8% for sorafenib and nilotinib, respectively. Sorafenib and nilotinib calibration curves were linear between 500 and 20000 ng/mL and 5 and 5000 ng/mL respectively, with correlation coefficients higher than 0.998. Analytes were determined in a 15 min run-time. The validated LC-MS method was applied in real human plasma routine analysis. This method may improve dose adjustment of the drugs in patients involved in cancer therapy.
英文关键词	sorafenib nilotinib human plasma SPE-LC-MS
类型	Article
语种	英语
开放获取类型	gold
收录类别	SCI-E
WOS记录号	WOS:001098344200017
WOS关键词	TYROSINE KINASE INHIBITORS ; SIMULTANEOUS QUANTIFICATION ; DIHYDRODIOL-METABOLITE ; MS/MS APPLICATION ; RAT PLASMA ; IBRUTINIB ; VALIDATION
WOS类目	Pharmacology & Pharmacy
WOS研究方向	Pharmacology & Pharmacy
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/396349
推荐引用方式 GB/T 7714	Popescu, Monica Denisa Elena,Manda, Costel-Valentin,Calucica, Daniela Maria,et al. QUANTITATIVE ANALYSIS OF SORAFENIB AND NILOTINIB IN HUMAN PLASMA BY SPE-LC-MS[J],2023,71(5):1024-1031.
APA	Popescu, Monica Denisa Elena.,Manda, Costel-Valentin.,Calucica, Daniela Maria.,Gaman, Amelia Maria.,Neamtu, Johny.,...&Croitoru, Octavian.(2023).QUANTITATIVE ANALYSIS OF SORAFENIB AND NILOTINIB IN HUMAN PLASMA BY SPE-LC-MS.FARMACIA,71(5),1024-1031.
MLA	Popescu, Monica Denisa Elena,et al."QUANTITATIVE ANALYSIS OF SORAFENIB AND NILOTINIB IN HUMAN PLASMA BY SPE-LC-MS".FARMACIA 71.5(2023):1024-1031.